Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-14
2009-06-23
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252120, C514S341000, C514S342000, C514S350000, C546S269700, C546S270400, C546S271400, C546S272700, C544S215000
Reexamination Certificate
active
07550463
ABSTRACT:
An object of the present invention provides a novel compound having the anti-viral activity, particularly, the HIV integrase inhibitory activity, and a drug containing the same, particularly, an anti-HIV drug.There is provided a compound represented by the formula:wherein,Y is NR4(R4is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aralkyl), O, S, SO, or SO2;RAis 1) a group represented by the formula: —COR5(wherein R5is a group selected from a substituent group A), or 2) a group represented by the formula:(wherein A C ring is an optionally substituted nitrogen-containing aromatic heterocycle in which, among atoms adjacent to an atom having a bond, at least one atom is an unsaturated nitrogen atom, and a broken line represents the presence or the absence of a bond);R1is a hydrogen or lower alkyl;X is a single bond, a hetero atom group selected from O, S, SO, SO2and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene;R2is a group selected from a substituent group A;R3is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted amino, optionally substituted lower alkylamino, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclic group, or optionally substituted heterocyclic lower alkyl)or a pharmaceutically acceptable salt thereof, or a solvate thereof.
REFERENCES:
patent: 6645956 (2003-11-01), Fujishita et al.
patent: 2004/0002485 (2004-01-01), Fujishita et al.
patent: 2004/0110804 (2004-06-01), Walker et al.
patent: 2004/0229909 (2004-11-01), Kiyama et al.
patent: 2005/0054645 (2005-03-01), Miyazaki et al.
patent: 2005/0075356 (2005-04-01), Di Francesco et al.
patent: 2005/0176767 (2005-08-01), Chan Chun Kong et al.
patent: 1 544 199 (2005-06-01), None
patent: 02-108668 (1990-04-01), None
patent: 02-108683 (1990-04-01), None
patent: 2004-244320 (2004-09-01), None
patent: 00/39086 (2000-07-01), None
patent: 03/016275 (2003-02-01), None
patent: 03/035076 (2003-05-01), None
patent: 2004/004657 (2004-01-01), None
patent: 2004/024693 (2004-03-01), None
patent: 2005/042524 (2005-05-01), None
Pace et. al., “The monoethyl ester of moeconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase”, Bioorganic & Medicinal Chemistry Letters 14 (2004) 3257-3261.
Hcaplus 138:204936.
Hcaplus 87:14971a, 14974a.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
S. Tewtrakul et al., “Flavanone and Flavonol Glycosides from the Leaves ofThevetia peruviannaand their HIV-1 Reverse Transcriptase and HIV-1 Integrase Inhibitory Activities”, Chem. Phar. Bull, vol. 50, No. 5, pp. 630-635, May 2002.
Andres Janet L.
Robinson Binta M
Shionogi & Co. Ltd.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Carbamoylpyridone derivatives having inhibitory activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamoylpyridone derivatives having inhibitory activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamoylpyridone derivatives having inhibitory activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142865